MedTrace Logo

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

NCT02076620 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-04-04

No results posted yet for this study

Summary

Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.

Conditions

  • Advanced Solid Tumors Amenable to Anthracycline Therapy
  • Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy

Interventions

DRUG

L19TNFα

L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.

DRUG

Doxorubicin

Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Principal Investigators

  • Filippo De Braud, Dr · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

  • Christoph Schliemann, Dr · Universitätsklinikum Münster

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-16
Primary Completion
2018-01-25
Completion
2018-01-25

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076620 on ClinicalTrials.gov